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Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in patients with neurofibromatosis type 1. In
2002, anMPNST consensus statement reviewed the current knowledge and provided guidance for the diagnosis andmanagement of
MPNST. Although the improvement in clinical outcome has not changed, substantial progress has beenmade in understanding the
natural history and biology of MPNST through imaging and genomic advances since 2002. Genetically engineered mouse models
that developMPNST spontaneously have greatly facilitated preclinical evaluation of novel drugs for translation into clinical trials led
by consortia efforts. Continued work in identifying alterations that contribute to the transformation, progression, and metastasis
of MPNST coupled with longitudinal follow-up, biobanking, and data sharing is needed to develop prognostic biomarkers and
effective prevention and therapeutic strategies for MPNST.
1. Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant,
pan-ethnic disorder with an incidence of 1 : 3000 [1]. NF1 is
characterized by diverse, progressive cutaneous, neurologic,
skeletal, and neoplasticmanifestationswith limited therapeu-
tic options. The leading cause of death in NF1 patients is the
malignant peripheral nerve sheath tumor (MPNST), a highly
aggressive soft tissue sarcoma [2]. Half of all MPNST develop
in individuals with NF1, with a 5-year survival of about
20% to 50%, and the outcome is especially dismal in those
with unresectable or metastatic disease [2, 3]. Most (65–88%)
NF1 MPNST arise from plexiform neurofibromas (PN) [4],
benign peripheral nerve sheath tumors that are a hallmark
of NF1. The only known definitive therapy for MPNST is
surgical resection with wide negative margins [4, 5], which
is often not feasible or indicated due to location, size, and
metastases [6, 7].
A 2002 MPNST consensus statement reviewed current
knowledge, provided guidance for the diagnosis andmanage-
ment of MPNST, and identified research priorities [8]. While
little progress has been made in the development of more
effective therapies since then, there have been substantial
advances in understanding MPNST natural history, biology,
and preclinical modeling, and preclinical and clinical trial
consortia have been established (Table 1). In this review,
we update progress since 2002 in the (1) natural history of
peripheral nerve sheath tumors, (2) pathogenesis of MPNST,
(3) development of preclinical models, and (4) management
and clinical trials for MPNST.
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Table 1: Summary of progress in preclinical, clinical, and therapeutic MPNST research and clinical management since the 2002 international
consensus conference.
Characteristic 2002 2016
Natural history of PN
growth
(i) Unknown
(ii) May be erratic
(i) Well characterized
(ii) Identification of distinct nodular lesions (DNL)
with different growth pattern
Imaging (i) Role of FDG-PET unclear(ii) FLT PET should be considered
(i) FDG-PET has clear role
(ii) FLT-PET under evaluation
Pathology
(i) ANF do not fit in category
(ii) Locally aggressive
(iii) Do not metastasize
(i) Identification of ANF as MPNST precursor
Risk for transformation ↑ (i) Nodular PN, large central PN, NF neuropathy (i) Distinct nodular, FDG-avid lesions
Pathogenesis (i) NF1microdeletion(ii) p27, p53, p16
(i) CDKN2A/B
(ii) SUZ12, EED
Mouse models (i) Briefly mentioned (i) Preclinical trials consortium using GEMM
Chemotherapy targeted
therapy (i) Very few, if any, MPNST-specific data
(i) Prospective trial of chemotherapy completed
(ii) MPNST-specific targeted trials ongoing
(iii) SARC and NF clinical trials consortium
Access to tissue (i) Importance of tissue banking (i) CTF NF biobank
Data collection (i) International database recommended (i) No international database established
ANF: atypical neurofibroma; DNL: distinct nodular lesion; FDG-PET: fluorodeoxyglucose positron emission tomography; FLT-PET: fluorothymidine
positron emission tomography; GEMM: genetically engineered mouse model; PN: plexiform neurofibroma; SARC: Sarcoma Alliance for Research through
Collaboration (research and advocacy group); CTF: Children’s Tumor Foundation.
2. Natural History of Peripheral Nerve
Sheath Tumors
PN, a cardinal feature of NF1, are identified in up to 50% of
individuals with NF1 [9]. They are a major source of morbid-
ity [10], causing disfigurement, impairment of nerve function,
pain, and in some cases transform toMPNST (Figure 1) [2, 3].
Magnetic resonance imaging (MRI) and fluorodeoxyglucose-
(FDG-) positron emission tomography (PET) are utilized in
the diagnosis ofmalignant transformationwith features to aid
in distinguishing MPNST from PN [11–14]. Since 2002, the
use of whole-body and targeted longitudinal MRI with volu-
metric analysis has permitted the sensitive and reproducible
characterization of PN growth [15–19]. Most PN growth
occurs in children, and substantial PN volume increase is
infrequent in adults. This is in contrast to distinct nodular
lesions (DNL) which have been identified using longitudinal
whole-body MRI and display different imaging and growth
characteristics [20, 21]. On Short T1 Inversion Recovery
(STIR) MRI, these lesions are nodular, ≥3 cm in longest
diameter, and well demarcated and lack the “central dot” sign
characteristic of PN. MRI imaging for MPNST demonstrate
irregularly shaped, ill-defined margins, intratumoral lobula-
tion, and inhomogeneous contrast enhancement [12]. DNL
emerge after early childhood, their growth rate is not age-
related, and they are frequently higher than that of surround-
ing or adjacent PN. In contrast to typical PN, most DNL
are FDG-avid on FDG-PET [21, 22] more like MPNST [13].
Biopsy and excision of some radiographically detected DNL
reveal histologically atypical neurofibromas (ANF). ANF
share some features of low-grade MPNST and recognition of
transformation of ANF toMPNST suggests that ANF are pre-
malignant lesions of MPNST rather than variants of PN [23].
ANF have increased variable cellularity and have cells with
enlarged, hyperchromatic nuclei andmore pronounced fasci-
cular growth [23, 24]. Taken together, these findings suggest
that DNL have a distinct underlying biology compared to
PN [20]. Genomic findings of CDKN2A/B loss in ANF and
MPNST (but not PN) further support the hypothesis that
ANF are precursor lesions for MPNST [22, 23, 25]. In a
retrospective analysis of 76 ANF diagnosed in 63 patients
with NF1, the majority (𝑛 = 57) were resected and have
not recurred [22]. However, four ANF transformed into high
grade MPNST. Sixteen patients had a history or developed
MPNST in a different location, and patients withANFmay be
at greater risk of developingMPNST [22]. Limited correlation
of clinical outcome in surgical excision of ANF suggests that
these lesions may not require aggressive surgery as MPNST.
In a retrospective review of 23 patients who underwent surgi-
cal resection of a plexiform neurofibroma pathologically
diagnosed as either low-grade MPNST or ANF had disease-
specific survival of 100% with a median follow-up of 47
months despite 78% (18/23) of patients having microscopi-
cally positivemargins [26].No patients developed pulmonary
metastasis. Further study is warranted, but focal surgical
resection of premalignant ANF may play an important role
in the prevention of MPNST.
3. Pathology of MPNST
Sarcoma arising from the peripheral nerve sheath is readily
diagnosed as MPNST if the tumor clearly has nerve elements
or arises in the context of NF1. Otherwise, the diagnosis of
MPNST is more difficult, with a broad differential diagnosis
of other sarcomas, and requires an extensive clinicopatho-
logic assessment of immunohistochemical (IHC) markers,
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Figure 1: Pathogenesis of peripheral nerve sheath tumors in NF1. Percentages below each tumor type is the range of lifetime prevalence in
individuals with NF1. Representative clinical photograph (a), MRI imaging (b), histology (c), clinical symptomology (d), and genetic features
(e) of each tumor type are given. Histologically, plexiform neurofibroma shows mixture of areas of hypercellularity in the absence of other
atypical features. Atypical neurofibroma shows atypical nuclei and higher cellularity. In contrast, MPNST are highly cellular with highmitotic
activity and areas of necrosis.
tissue ultrastructure, and histologic findings [24, 27] to firmly
establish a tumor diagnosis. High-grade MPNST are highly
cellular withmanymitotic figures and areas of necrosis. Low-
gradeMPNSTare less cellular, have fewmitotic figures andno
areas of necrosis, and are difficult to distinguish from benign
cellular neurofibromas and ANF. Various histologic patterns
can coexist within a single specimen, making it imperative
to examine as much of the tumor as possible to arrive at an
appropriate diagnosis and grade [28]. Small biopsies are usu-
ally inadequate for clinical decision-making due to this intra-
tumor heterogeneity.
IHC studies are helpful in distinguishing high-grade
MPNST from other sarcomas but are less helpful in dis-
tinguishing ANF from low-grade MPNST. Typical staining
includes in situ antibody studies on multiple formalin-fixed
sections for S100 (calcium-binding motif as Schwann cell
marker), Ki-67 (nuclear nonhistone protein marker of cell
proliferation), TP53 (tumor suppressor marker for trans-
formation), CD34 (sialomucin glycoprotein as nonspecific
marker of endothelium and hematopoietic stem cells), and
p16INK4a (cell-cycle inhibitory protein marker that is inac-
tivated in MPNST). A standardized set of IHC markers has
not been routinely applied to peripheral nerve sheath tumors
across clinical pathology laboratories. Although they may be
useful in characterizing MPNST [29], the pattern of IHC
staining has not led to stratification of patients for person-
alized management of their tumor. Use of genetic markers
in these tumors is emerging as another modality to more
fully characterize peripheral nerve sheath tumors for clinical
intervention.
4. Genetics and Genomics of MPNST
MPNST cells harbor complex rearranged genomes. Accumu-
lated evidence suggests thatNF1 loss is necessary but not suf-
ficient for MPNST development. As NF1-associated MPNST
progress fromNF1-nullizygous PN, they acquiremutations in
other driver genes (e.g. TP53 and CDKN2A). NF1 loss is seen
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in a majority of sporadic MPNST, suggesting that NF1 is an
important tumor suppressor in all MPNST. Genetic alter-
ations of CDKN2A and TP53 are also observed in sporadic
and radiation-associated MPNST [30]. Deletion of CDKN2A
disrupts two encoded proteins (p16INK4A and p19ARF) and
their associated regulatory cascades. CDKN2A deletions are
also observed in ANF [23]. The first study of NF1-associated
tumor progression in a single patient from PN to primary
MPNST andMPNSTmetastasis usingwhole exome sequenc-
ing (WES) of biopsies [31] found biallelic NF1 mutations in
all tumor stages, chromosome 17p (TP53) loss in primary
MPNST and metastasis, and no CDKN2A deletions or EGFR
amplifications. Subsequent cytogenetic and array compara-
tive genomic hybridization (aCGH) studies on MPNST have
identified frequent losses on chromosomes 1p, 9p, 11, 12p,
14q, 18, 22q, X, and Y, with focal gains on chromosomes 7,
8q, and 15q [32]. There are no pathognomonic chromosomal
translocations in MPNST. Amplification of genes encoding
the epidermal growth factor (EGF) receptor, neuregulin-1
(NRG1) coreceptor erbB2, c-Kit, platelet-derived growth fac-
tor-𝛼, and c-Met has been reported in MPNST [33].
In 2014, somatic mutations in SUZ12 and EED encoding
components of the polycomb repressive complex 2 (PRC2)
were reported in NF1-associated and sporadic MPNST [30,
34, 35]. PRC2 is a histone methyltransferase and plays a
critical role in marking chromatin for silencing. This finding
suggests that transformation to MPNST involves a previ-
ously unsuspected epigenetic switch and points to poten-
tial epigenetic-based therapeutic strategies. Comprehensive
genomic characterization of sporadic, NF1-, and radiation-
associated MPNST shows recurrent inactivation of PRC2
from somaticmutation ofEED and SUZ12 [30, 35].The SUZ12
gene encodes a chromatin modifying protein, and its loss
enhances colony growth of NF1-deficient (but not NF1 wild-
type) glioblastoma cells, suggesting that reduced PRC2 levels
might promote tumorigenesis. Furthermore, SUZ12 ablation
causes loss of trimethylation at lysine 27 of histone H3
(H3K27me3) and increased H3K27 acetylation, establishing
transcriptional activation marks to recruit bromodomain
proteins that are potential drug targets for MPNST [34].
Frequent somatic alterations of CDKN2A andNF1 signif-
icantly co-occur with PRC2 alteration. SUZ12 is located near
NF1 in 17q11.2 and is involved in both type 1 and type 2micro-
deletions at theNF1 locus. Suchmicrodeletions are associated
with an increased risk of MPNST [36], leading to a model
in which a “third hit” in SUZ12 (the first two hits being the
loss of NF1 and one copy of SUZ12 from a 17q11.2 microdele-
tion) drives transformation to MPNST [30]. PRC2 catalyzes
trimethylation ofH3K27 andmultiple studies have found that
significant loss of H3K27me3 in MPNST is associated with
poor survival; furthermore, such loss is not observed in PN
or ANF [37–39]. H3K27me3 loss or PRC2 mutation may be a
useful biomarker to diagnose MPNST [35].
5. Preclinical Models
The primary model systems used to study MPNST have been
(1) cell lines derived from MPNST patients, (2) xenograft
models of patient-derived MPNST cells injected subcuta-
neously or into the sciatic nerve of immune compromised
mice, (3) patient-derived xenografts (PDX) that have not been
cultured, and (4) genetically engineered mouse models of
sporadic MPNST.
5.1. Cell Culture Models. MPNST tumor lines from human
and mouse have been used to elucidate the mechanism of
action of neurofibromin [40]; study the role of tyrosine kinase
receptors [41–47], growth factors [48–50], p53 [51, 52],micro-
RNAs [30, 53], and sex hormones [54–56] inMPNSTbiology;
and examine the effects of chemotherapy [57–67] and viral
therapy [68–71] as potential treatments forMPNST.Themost
commonly used strains for grafting have been S462, ST88-
14, and STS26T. STS26T was isolated from ametastatic lesion
and has been shown to form metastases when injected into
the tail vein of the mouse [62].
At least 33 NF1 or sporadic MPNST lines from primary
or metastatic human tumors and mice tumors have been
described in the literature to varying degrees (Supplemental
Table 1, in SupplementaryMaterial available online at https://
doi.org/10.1155/2017/7429697). Mouse tumor lines have been
made by isolating tumors with MPNST histology from
Nf1−/+:Trp53−/+cismice (see below).
5.2. Xenograft/Orthograft Models. Over half of the described
MPNST tumor lines have been used in grafting experiments
to recapitulate the biology ofMPNST inmice.Themajority of
these experiments studied human MPNST cells in immune-
deficient mice. Although some cancer cell types are known
to grow only on certain immune-deficient backgrounds
(e.g., NSG), MPNST cells can engraft in hosts with residual
immune function. MPNST cell lines that have been reported
to engraft inmice and the type ofmouse background used are
listed in Supplemental Table 1. Xenograft models have been
primarily used to test candidate therapeutics for MPNST.
5.3. Patient-Derived Xenograft (PDX) Models. Culture and
xenograft models have been the mainstay of testing novel
therapeutics for MPNST over the past 20 years. There is con-
troversy regarding how well these models predict response
in patients. This has led to the development of additional
models that seek to better emulate the tumor microenviron-
ment. Tumor cells passaged in culture adapt to the lack of
extracellular matrix and culture-specific exogenous growth
factors. PDXmodels are created by implanting patient tumor
tissue directly into immune-deficient mice, so that the tumor
cells grow directly within an in vivo environment. Very few of
these models have been published. It is not clear how many
have been maintained by passaging for use by other inves-
tigators. Bhola et al. [55] isolated tumor tissue from a male
young adult NF1 patient and implanted small pieces subcu-
taneously into male NOD/SCID mice. The explants retained
the histological and IHC characteristics of the parental tumor
over more than 15 passages [72, 73].
5.4. Genetically EngineeredMouseModels (GEMMs). GEMMs
develop MPNST spontaneously, permitting the coevolution
Sarcoma 5
Table 2: Genetically engineered mouse models (GEMMs).







Nf1−/+; Ink4a−/−; Arf−/− Germline1 High 6.5 26 [79]
Nf1flox/flox; Ptenflox/flox Cre (Dhh+ cells) High 0.5 92 [80]
Nf1flox/flox; Ptenflox/+ Cre (Dhh+ cells) Low 5.7 42 [80]
Nf1flox/+; Ptenflox/flox Cre (Dhh+ cells) Low 5.8 82 [80]
Nf1flox/flox + Nf1; p53shRNA Cre (Periostin+ cells)4 Low 6.1 56 [87]
Nf1flox/− + Nf1; p53shRNA Cre (GFAP+ cells)4 Low 3.0 73 [87]
Nf1flox/flox; Ink4aflox/flox; Arfflox/flox Cre (injection) High 4.1 100 [86]
Nf1−/+:Trp53−/+ Germline2 High 5 81 [77, 78]
Nf1flox/flox Cre (Dhh+ cells) EGFR CNP High ∼6 33 [81]
Trp53−/+ Germline3 EGFR CNP Low-high 9.5 19 [84]
Ptenflox/+ Cre (GFAP+ cells) Kras-G12D lox-STOP-lox5 High ∼6 100 [82]
Ptenflox/flox Cre (Dhh+ cells) EGFR CNP High <1 100 [83]
Trp53−/+ Germline3 GGF𝛽3 P0 Low-high 7.5 95 [57]
NA NA GGF𝛽3 P0 ND 8.7 71 [85]
1Spontaneous loss of NF1; 2spontaneous loss of NF1 and p53; 3spontaneous loss of p53; 4injection of shRNA into sciatic nerve; 5activation by Cre (GFAP+ cells).
NA: not applicable; ND: not determined.
of microenvironment and tumor. One GEMM (Nf1−/+:
Trp53−/+cis mice) is being used for preclinical screening
of drugs through the NF Therapeutic Consortium (NFTC)
[34, 74–76]. The available GEMMs for MPNST use several
approaches to initiate tumorigenesis: (1) spontaneous loss of
heterozygosity of tumor suppressor genes, (2) expression of
oncogenes by nervous system promoters, (3) Cre-lox system
for mutation or conditional activation of genes during nerve
development, or (4) adenoviral or lentiviral expression of
shRNAs (Table 2). Heterozygous mutation of Nf1 alone is not
sufficient to drive MPNST tumorigenesis in mice; however,
combining Nf1 mutation with other mutations (Trp53, Pten,
and Cdkn2a) gives rise to MPNST. In addition, MPNST
GEMMshave been developedwithoutmutation ofNf1, possi-
bly recapitulating sporadicMPNST.ThefirstMPNSTGEMM
was the Nf1−/+:Trp53−/+cis mouse [77, 78] with mutated
copies of Nf1 and Trp53 in cis on mouse chromosome 11.
Spontaneous loss of the wild-type alleles of these genes
initiates tumorigenesis. Combining Nf1 heterozygosity with
loss of Cdkn2a, encoding p16INK4A and p19ARF, gives rise to
MPNST with low penetrance [79]. The Cre-lox system has
been used in several GEMMs to mutate Nf1, Trp53, Pten,
and/orCdkn2a in cells of the developing nervous system [80–
83], as well as to activate mutant Kras [82]. Some GEMMs
have combined overexpression of the oncogenes Egfr or
Ggfb3 with tumor suppressor mutation by driving oncogene
expression in nervous system cells using CNP or 𝑃0 promot-
ers, respectively [57, 80, 81, 84, 85]. More recently, MPNSTs
have been modeled using injections into adult mouse sciatic
nerve. Injection of adenovirus expressing Cre into mice
carrying floxed alleles of Nf1 and Cdkn2a drives high-grade
MPNST through localized loss of neurofibromin, p16Ink4a,
and p19Arf in the nerve [86]. Low-grade MPNSTs form with
the injection of shRNA for both Nf1 and Trp53 into mice that
are either mutant for Nf1 in all Periostin+ cells or mutant for
Nf1 in GFAP+ cells on a heterozygousmutantNf1 background
[87]. Injection GEMMs have the advantage that tumorigen-
esis occurs in a more synchronized and spatially controlled
manner; however, they require surgery for every mouse to
expose the sciatic nerve for injection. GEMMs show different
latencies for MPNST depending on the genes involved
(Cdkn2a, Pten, Trp53, and Egfr) and the method used to
mutate genes (shRNA knockdown versus genomic mutation
through the Cre-lox system) (Table 2).
6. Clinical Trials Advances
Current treatment of MPNST is similar to treatment of soft
tissue sarcomas as a whole and relies primarily on local
control measures [5]. The only known definitive therapy for
MPNST is surgical resection with wide negative margins,
whichmay not be feasible due to variables such as tumor size,
location, and/ormetastases [7].The role of adjuvant radiation
is not defined; however, it is often recommended for high-
grade lesions > 5 cm in size or with marginal excision [8,
88, 89]. For these patients, preoperative radiation should be
considered [90]. Although radiation has shown improved
local control, no effect on survival has been demonstrated
[91, 92].The role of chemotherapy is not defined. In a prospec-
tive study of chemotherapy (ifosfamide, doxorubicin, and
etoposide) in NF1 associated and sporadic MPNST, a lower
objective response rate was seen in NF1 patients (18%) com-
pared with patients with sporadic MPNST patients (44%),
similar to prior studies [93, 94]; however, disease stabilization
was achieved in most patients at 4 cycles [95]. The best
approach to treatment is by a multidisciplinary team of
surgical, medical, and radiation oncologists, radiologists, and
pathologists, all with sarcoma expertise. Patients with recur-
rent, unresectable, or metastatic disease have no known
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Table 3: Targeted agents for treatment of MPNST: previous and ongoing clinical trials.
Drug Target Phase 𝑛 Population Outcome Results Ref.

























Dasatinib C-Kit SRC II 14 ≥13 yRefractory
Response
CHOI [103] No response or SD [99]




PFS 13 weeks [100]
Bevacizumab/RAD001 Angiogenesis/mTOR II — ≥18 yRefractory
Response
WHO [101] Currently ongoing —




WHO [101] Currently ongoing —
curative options and enrollment in clinical trials should be
considered.
The EGFR inhibitor erlotinib was the first targeted agent
used in a histology-specific phase II trial for MPNST [96],
based on the compelling preclinical observation that EGFR
amplification was observed in MPNSTs and that Nf1/p53
murine MPNST were stimulated by EGF and inhibited by
EGFR inhibitors [33]. Within 22 months, 24 patients were
enrolled, but no activity was demonstrated. Subsequent trials
of investigational agents (Table 3) have failed to demonstrate
efficacy but show that the outcome for unresectable MPNST
is poor with a median progression-free survival of less than 2
months and overall survival of less than 5 months [97–100].
These trials demonstrate that single histology trials in this
rare disease are feasible and that MPNST progresses rapidly.
Selection, prioritization, and trial design are key chal-
lenges in the clinical development of effective therapies for
MPNST. While preclinical drug discovery outpaces clinical
development, the time and cost to evaluate promising ther-
apies for MPNST are significant and patient numbers are
limited. The Children’s Tumor Foundation (CTF) and Neu-
rofibromatosis Therapeutic Acceleration Program (NTAP)
sponsor the preclinical NFTherapeutic Consortium (NFTC),
which supports the conduct of preclinical trials of targeted
therapies in GEMM targeting NF1 manifestations (e.g.,
MPNST and PN) to prioritize the selection of agents for
clinical trials. There are no data yet demonstrating MPNST
GEMM as valid surrogates for drug activity in humans.
Through clinical consortia initiatives such as the Department
of Defense (DoD) NF Clinical Trials Consortium and the
SARC (Sarcoma Alliance for Research through Collabora-
tion), therapies identified through these models are being
translated into clinical trials specific forMPNST. Cooperative
group participation allows for rapid accrual for early phase
trials in MPNST. Approaches to accelerating testing of agents
guided by preclinical rationale, with efficient endpoints,
protocol design, and access to drugs, are needed. In turn,
these trials can serve as a means to not only validate the best
preclinical models, and information gained in the clinic can
be used to help develop new therapeutic approaches at the
bench.
7. Future Directions
Although the outcome for MPNST has not changed signif-
icantly since 2002, the more complete understanding of the
natural history of peripheral nerve sheath tumors and of the
genomic changes during malignant transformation of PN to
ANF and MPNST offers hope for the development of more
effective diagnostic, therapeutic, and prevention strategies for
MPNST.Whole-bodyMRI and PET imagingmay have utility
for risk stratification and for implementation of surveillance
and medical/surgical interventions as potential preventative
therapies and for monitoring treatment response in large,
irregular-shaped tumors. Research priorities should focus on
the role of whole-body MRI to screen for PN-related tumor
load andon longitudinal imaging to detect lesions concerning
malignant transformation, such as DNL. The natural history
of ANF needs to be better understood, including its clinical
presentation, incidence of malignant transformation of DNL
to ANF, and the role for timing and extent (wide versus
limited) of surgical excision of these transitional tumors,
while resource-intensive, prospective, longitudinal studies of
individualswithNF1 andPNwithwhole-bodyMRI and other
imaging modalities coupled with genomic and immunohis-
tological data and collection of blood samples for potential
biomarker development are predicted to have great value in
advancing approaches to the diagnosis, treatment, and pre-
vention of MPNST.
Great strides have been made in the development of
preclinical models for understanding disease pathogenesis
and drug testing in MPNST. Translating and validating pre-
clinical models will require developing validated biomarkers
of disease and outcomemeasures using new technologies that
can be incorporated into clinical trials.The search forMPNST
biomarkers must have new urgency. Circulating tumor DNA
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is essentially unstudied in MPNST and may offer great
promise to screen and detect early cancers, score treatment
response, and identify tumor recurrence. The importance of
epigenetic mechanisms in MPNST pathogenesis has been
underappreciated until the advent of comprehensive genomic
studies which have offered clues to future therapies. An
international MPNST database with phenotypic, genotypic,
and treatment data is needed to share findings and inform
next steps for research efforts and treatment strategies [104].
The tumor phenotype data should be comprehensive and
include complete characterization of the tumors from clinical
pathologists with expertise in sarcoma. To that end, standard
and broadly accepted definitions of what constitutes benign
cellular neurofibroma, DNL, ANF, low-grade MPNST, and
high-grade MPNST need to be established. Molecular data
needed for theMPNST database include constitutional DNA,
tumor DNA, tumor expression patterns, circulating cell-free
DNA, and possiblymetabolic activity of the tumor. Treatment
and outcome data need to be collated with the genotype-
phenotype information in the database. Innovative clinical
trial designs with efficient endpoints to accelerate testing of
new drugs and access to novel agents for testing in combina-
tion are also needed.
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